- Pharmaceutical giant AstraZeneca is set to invest £300 million into UK drug development, a commitment announced by Sir Keir Starmer.
- This investment follows a US-UK agreement, finalised in April, aimed at increasing medicine prices in Britain.
- The new funding marks a change in direction after AstraZeneca previously paused a £200 million expansion in Cambridge and scrapped plans for a £450 million vaccine plant in Merseyside.
- Sir Keir Starmer hailed the investment as “significant”, stating it would “futureproof thousands of jobs” in Macclesfield and Cambridge.
- The funds will be used to complete the Rosalind Franklin building on AstraZeneca's Cambridge campus and to develop a 'lab of the future' in Macclesfield, utilising digital and data tools for drug development.
IN FULL
